196 related articles for article (PubMed ID: 32273145)
1. Patients' understanding of oncology clinical endpoints: A literature review.
Boudewyns V; Southwell BG; DeFrank JT; Ferriola-Bruckenstein K; Halpern MT; O'Donoghue AC; Sullivan HW
Patient Educ Couns; 2020 Sep; 103(9):1724-1735. PubMed ID: 32273145
[TBL] [Abstract][Full Text] [Related]
2. Patients' Understanding of Oncology Clinical Endpoints: Environmental Scan and Focus Groups.
Sullivan HW; O'Donoghue AC; Ferriola-Bruckenstein K; Tzeng JP; Boudewyns V
Oncologist; 2020 Dec; 25(12):1060-1066. PubMed ID: 32799406
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Endpoints in paediatric oncology.
Paolucci P; Cioni V; Bigi E; Lucaccioni L; Cano C
Eur J Clin Pharmacol; 2011 May; 67 Suppl 1():33-40. PubMed ID: 21085937
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
Herzog TJ; Armstrong DK; Brady MF; Coleman RL; Einstein MH; Monk BJ; Mannel RS; Thigpen JT; Umpierre SA; Villella JA; Alvarez RD
Gynecol Oncol; 2014 Jan; 132(1):8-17. PubMed ID: 24239753
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of outcomes and endpoints in acute migraine clinical trials.
Houts CR; McGinley JS; Nishida TK; Buse DC; Wirth RJ; Dodick DW; Goadsby PJ; Lipton RB
Headache; 2021 Feb; 61(2):263-275. PubMed ID: 33611818
[TBL] [Abstract][Full Text] [Related]
7. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and endpoints in cancer trials: bridging the divide.
Wilson MK; Collyar D; Chingos DT; Friedlander M; Ho TW; Karakasis K; Kaye S; Parmar MK; Sydes MR; Tannock IF; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e43-52. PubMed ID: 25638556
[TBL] [Abstract][Full Text] [Related]
9. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
10. Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.
Liberti L; Stolk P; McAuslane JN; Schellens J; Breckenridge AM; Leufkens H
Oncologist; 2015 Jun; 20(6):683-91. PubMed ID: 25948678
[TBL] [Abstract][Full Text] [Related]
11. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
12. The importance of quality-of-life endpoints in clinical trials to the practicing oncologist.
Passik SD; Kirsh KL
Hematol Oncol Clin North Am; 2000 Aug; 14(4):877-86. PubMed ID: 10949778
[TBL] [Abstract][Full Text] [Related]
13. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
14. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.
Zichi C; Paratore C; Gargiulo P; Mariniello A; Reale ML; Audisio M; Bungaro M; Caglio A; Gamba T; Perrone F; Di Maio M
Eur J Cancer; 2021 May; 149():49-60. PubMed ID: 33823362
[TBL] [Abstract][Full Text] [Related]
15. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
16. Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
A'Hern RP
J Clin Oncol; 2016 Oct; 34(28):3474-6. PubMed ID: 27507871
[No Abstract] [Full Text] [Related]
17. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology.
Serpas VJ; Raghav KP; Halperin DM; Yao J; Overman MJ
BMC Med Res Methodol; 2018 Dec; 18(1):169. PubMed ID: 30541475
[TBL] [Abstract][Full Text] [Related]
18. Telephone interventions for symptom management in adults with cancer.
Ream E; Hughes AE; Cox A; Skarparis K; Richardson A; Pedersen VH; Wiseman T; Forbes A; Bryant A
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD007568. PubMed ID: 32483832
[TBL] [Abstract][Full Text] [Related]
19. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
20. Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?
Johnson P; Greiner W; Al-Dakkak I; Wagner S
Biomed Res Int; 2015; 2015():865101. PubMed ID: 26161418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
